Canada Markets close in 45 mins

Mesoblast Limited (LWBA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.1400-0.0600 (-1.87%)
As of 03:32PM CET. Market open.
Full screen
Loading interactive chart...
  • GlobeNewswire

    Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

    Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults1-4These results reaffirm the potential significance of remestemcel-L as a life-saving therapy for children with SR-aGVHDThese long-term survival outcome

  • GlobeNewswire

    Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022

    Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational high

  • GlobeNewswire

    Mesoblast Financial Results and Corporate Update Webcast

    NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2022. The webcast will begin at 4.30pm EST, Tuesday, November 22; 8.30am AEDT, Wednesday, November 23, 2022. It can be accessed via: https://webcast.openbriefing.com/9143/ The archived webcast will be available on the Inve